证券代码：300534 证券简称：陇神戎发 公告编号：2025-048 甘肃陇神戎发药业股份有限公司 2025年第三次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东会未出现否决议案的情形； 4.会议召集人：公司董事会 5.会议主持人：董事长康永红先生 6.本次股东会的召集、召开以及表决程序符合《公司法》等法律、行政法规、 部门规章、规范性文件和《公司章程》的规定。 2.本次股东会不涉及变更以往股东会已通过的决议的情形。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间： （1）现场会议召开时间：2025 年 6 月 17 日下午 14:00 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2025年6月17日9:15—9:25，9:30—11:30和13:00—15:00；通过深圳证券交易所 互联网投票系统进行网络投票的时间为2025年6月17日9:15—15:00期间的任意 时间。 2.现场会议地点：甘肃省兰州市榆中县定远镇国防路 10 号公司六楼会议室 3.会议召开方式：本次股东 ...

北京德恒（兰州）律师事务所 关于甘肃陇神戎发药业股份有限公司 2025 年第三次临时股东会 之 法律意见书 甘肃省兰州市城关区雁园路 601 号甘肃省商会大厦 A 座 15 层 邮编：730030 电话：（0931）8260111 传真：（0931）8456612 法律意见书 致：甘肃陇神戎发药业股份有限公司 北京德恒（兰州）律师事务所（以下简称"本所"）受甘肃陇神戎发药业股 份有限公司（以下简称"陇神戎发""贵公司""公司"）委托，指派范文泽、 张昕律师（以下简称"本所律师"）出席贵公司 2025 年第三次临时股东会（以 下简称"本次股东会"），并对本次股东会的合法性出具法律意见书。 关于甘肃陇神戎发药业股份有限公司 2025 年第三次临时股东会法律意见书 北京德恒（兰州）律师事务所 关于甘肃陇神戎发药业股份有限公司 2025 年第三次临时股东会之 本所律师列席了贵公司本次股东会，并根据本法律意见书出具日前已发生或 存在的事实和《中华人民共和国公司法》（以下简称《公司法》）、《中华人民 共和国证券法》（以下简称《证券法》）、《上市公司股东会规则》以及《甘肃 陇神戎发药业股份有限公司章程》（以下简称《公司章程 ...

Meeting Details - The meeting was held on June 17, 2025, at 14:00, with online voting available from 9:15 to 15:00 on the same day [1] - A total of 192 shareholders attended the meeting, representing 118,310,230 shares, which is 39.0019% of the company's total share capital [1][2] - Among the attendees, 4 were present at the venue, while 188 participated through proxy voting, representing 4,250,920 shares or 1.4070% of the voting shares [1] Voting Results - The meeting combined on-site and online voting for the proposals, with 118,203,930 shares voting in favor, accounting for 99.9958% of the voting shares [3] - Small shareholders voted with 4,161,720 shares in favor, representing 97.5094% of the small shareholders' voting shares [3][4] - The proposals were classified as special resolutions and received the necessary majority for approval [3][4] Legal Opinion - The legal representatives from Beijing Deheng (Lanzhou) Law Firm confirmed that the meeting's procedures complied with legal and regulatory requirements, and the resolutions passed were valid [10][11]

Core Viewpoint - Several listed companies in the Shanghai and Shenzhen markets announced significant updates, including changes in control, regulatory measures, and sales performance, which may present investment opportunities and risks for investors [2]. Company Announcements - Zhongying Electronics announced that its controlling shareholder is planning a change in control, leading to a suspension of trading from June 9, 2025, for up to two trading days [3]. - ST Lutong received an administrative regulatory measure from the Jiangsu Securities Regulatory Bureau due to internal control deficiencies and failure to disclose significant lawsuits and account freezes [4]. - Lianhua Technology clarified that it does not directly produce chlorantraniliprole and that the related matters have limited impact on its overall business [5]. - Longshen Rongfa's subsidiary received a CNAS laboratory accreditation certificate, which is expected to positively influence future operations, though it will not significantly impact current performance [6]. Sales Performance - Yisheng Co. reported a significant increase in May sales of breeding pigs, with a total of 10,849 heads sold, representing a year-on-year increase of 207.08% [7]. Shareholding Changes - Shentong Technology's shareholder, Biheng Investment, plans to reduce its stake by up to 3%, equating to a maximum of 12.88 million shares [8]. - Ruoyuchen's shareholder, Langzi Co., intends to reduce its stake by up to 3%, not exceeding 4.7681 million shares [9]. - Oujing Technology's shareholder, Wanzhao Huigu, plans to reduce its stake by up to 3%, equating to a maximum of 5.7722 million shares [10]. - Jindan Technology's shareholder, Guangzhou Chengxin, plans to reduce its stake by up to 2.93%, equating to a maximum of 5.635 million shares [11]. - Huashu Gaoke's shareholder, Guotou Chuangye Fund, plans to reduce its stake by up to 2.2%, equating to a maximum of 9.1117 million shares [12]. - Zhongke Soft's shareholder, Kesuan Chuangyuan, plans to reduce its stake by up to 2%, equating to a maximum of 16.6208 million shares [13]. - Hengrun Co. announced multiple shareholders planning to reduce their stakes, with total reductions not exceeding 1.89% of the company's shares [14]. - Del Shares' shareholder, Wuxu 15 Fund, plans to reduce its stake by up to 1.987%, equating to a maximum of 3 million shares [15]. - Jian Ke Yuan's shareholder, Jian Ke Investment, plans to reduce its stake by up to 1% [17]. - Mindong Electric's shareholder, Fujian Investment Development Group, plans to reduce its stake by up to 1% [18]. - Puli Software's chairman and executives plan to reduce their stakes by a total of up to 0.69% [19].

Group 1 - Zhongying Electronics' controlling shareholder is planning a change in control, leading to a stock suspension starting June 9, 2025, for up to 2 trading days [3] - Lianhua Technology clarified that it does not directly produce chlorantraniliprole, and the related matters have limited impact on the company's overall performance [4] - Longshen Rongfa's subsidiary received CNAS laboratory accreditation, which is expected to positively influence future operations, though it will not significantly impact current performance [5] Group 2 - Yisheng Co. reported May sales of breeding pigs at 10,849 heads, a year-on-year increase of 207.08%, with significant sales increases attributed to delayed orders from April [7] - Shentong Technology's shareholder plans to reduce its stake by up to 3%, amounting to no more than 12.88 million shares [9] - Ruoyuchen's major shareholder intends to reduce its stake by up to 3%, not exceeding 476.81 million shares [10] Group 3 - Oujing Technology's major shareholder plans to reduce its stake by up to 3%, not exceeding 577.22 million shares [12] - Jindan Technology's shareholder plans to reduce its stake by up to 2.93%, amounting to no more than 563.5 million shares [13] - Huashu Gaoke's shareholder intends to reduce its stake by up to 2.2%, not exceeding 911.17 million shares [14] Group 4 - Zhongke Soft's major shareholder plans to reduce its stake by up to 2%, not exceeding 16.62 million shares [15] - Hengrun Co.'s shareholders plan to collectively reduce their stake by up to 1.89%, with specific reductions from various shareholders [16] - Del Shares' shareholder plans to reduce its stake by up to 1.987%, not exceeding 3 million shares [17] Group 5 - Jianke Institute's shareholder plans to reduce its stake by up to 1%, not exceeding 146.66 million shares [18] - Mindong Electric's shareholder plans to reduce its stake by up to 1%, not exceeding 457.95 million shares [19] - Puli Software's chairman and executives plan to collectively reduce their stake by up to 0.69% [20]

证券代码：300534 证券简称：陇神戎发 公告编号：2025-047 甘肃陇神戎发药业股份有限公司 关于控股孙公司获得中国合格评定国家认可委员会 （CNAS）实验室认可证书的公告 一、证书基本信息 机构名称：甘肃药业集团国方检验检测有限公司 注册号：CNAS L23303 生效日期：2025 年 5 月 30 日 截止日期：2031 年 5 月 29 日 兹证明：甘肃药业集团国方检验检测有限公司符合 ISO/IEC 17025：2017《检 测和校准实验室能力的通用要求》（CNAS-CL01《检测和校准实验室能力认可准 则》）的要求，具备承担本证书附件所列服务能力，予以认可。获认可的能力范 围见标有相同认可注册号的证书附件，证书附件是本证书组成部分。 二、对公司的影响 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 甘肃陇神戎发药业股份有限公司（以下简称"公司"）控股孙公司甘肃药业 集团国方检验检测有限公司（以下简称"国方检测"）于近日收到中国合格评定 国家认可委员会（以下简称"CNAS"）授予的实验室认可证书，现将相关情况公 告如下： CNAS 是国家市场 ...

Core Viewpoint - Longshen Rongfa's subsidiary, Gansu Pharmaceutical Group Guofang Testing Co., Ltd., has received the CNAS laboratory accreditation certificate, indicating recognition of its management and technical capabilities at both national and international levels, which is expected to positively impact the company's future operations [1] Group 1 - The CNAS laboratory accreditation certificate signifies that Guofang Testing's laboratory management and technical capabilities have been recognized [1] - The acquisition of the certificate is anticipated to have a positive effect on the company's future business operations [1] - The certificate's attainment will not have a significant impact on the company's current operating performance [1]

Core Viewpoint - The company, Longshen Rongfa, emphasizes the significant role of its core product, Xuanfei Zhiso Heji, in the prevention and treatment of COVID-19 and influenza, highlighting its historical background, clinical efficacy, and market position as a key driver of revenue growth [1] Product Recognition and Market Position - Xuanfei Zhiso Heji has received multiple awards and recognitions, including the Gansu Province Science and Technology Progress Third Prize and the Gansu Province Pharmaceutical Society Development Award First Prize [2] - The product has been included in various prestigious lists, such as the 2021 TOP20 Traditional Chinese Medicine for cough relief and the 2024 list of recommended medications for respiratory diseases in Gansu Province [2] - The national protection period for the product has been successfully extended to July 20, 2030, enhancing its market exclusivity [2] Strategic Development and Research - The company is focusing on multi-dimensional strategic upgrades around Xuanfei Zhiso Heji, increasing R&D investments for product development and value enhancement [3] - Key projects include process optimization, evidence-based medicine development, and clinical trials, resulting in significant research outputs [3] - Future research will target specific conditions like post-COVID cough and chronic obstructive pulmonary disease (COPD) to establish unique advantages in treatment [3] Market Strategy and Expansion - The company implements a dual strategy of clinical and OTC (over-the-counter) market synchronization, aiming to enhance product recognition among healthcare professionals [3] - Efforts are being made to expand market coverage in hospitals and retail pharmacies, converting clinical acceptance into retail sales growth [3] Production Capacity and New Product Development - In May 2024, the company completed an upgrade of its production line for Xuanfei Zhiso Heji, achieving an annual production capacity of 50 million boxes (equivalent to 300 million units) [4] - The upgraded production line enhances automation and quality control, supporting stable supply and market expansion [4] - The company is also venturing into the health sector with new products like the herbal beverage "7° Feidele" and the solid drink "Huangqi Danggui Drink," targeting health-conscious consumers [4]

Core Insights - The company, Longshen Rongfa, is focusing on enhancing the market competitiveness of its flagship product, Xuanfei Zhiso Heji, which is a state-level new drug and included in national medical insurance [1][6] Group 1: Product Development and Research - The company is investing in research and innovation to enhance the value of Xuanfei Zhiso Heji, including secondary product development and establishing core technological barriers [2] - Research projects include process studies, evidence building for major product cultivation, real-world safety evaluations, and clinical efficacy trials, resulting in seven research outcomes and a comprehensive clinical evaluation report [2] - The product's protection period has been successfully extended to July 20, 2030, increasing its market competitiveness [1] Group 2: Market Expansion and Production Capacity - The company employs a strategy of synchronizing clinical and OTC (over-the-counter) markets, enhancing coverage in top-tier hospitals while expanding into untapped markets and retail pharmacies [3] - A significant upgrade to the production line was completed in May 2024, increasing annual production capacity to 50 million boxes (300 million units) and passing GMP compliance checks [3] Group 3: Brand Development and Cultural Promotion - The company is exploring brand extension with the development of a herbal beverage, "7° Feidele," to reach a broader consumer base [4] - Active participation in medical exhibitions and health industry forums aims to promote traditional Chinese medicine and enhance public awareness of the product's efficacy [4]

甘肃陇神戎发药业股份有限公司 内部控制制度 第一章 总则 第一条 为规范和加强甘肃陇神戎发药业股份有限公司（以下简称"公司"） 内部控制，提高公司经营管理水平和风险防范能力，保护投资者合法权益，根据 《中华人民共和国公司法》《中华人民共和国证券法》《企业内部控制基本规范》 《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指 引第 1 号—主板上市公司规范运作》等法律法规和《公司章程》的规定，结合公 司实际，制定本制度。 第二条 本制度所称内部控制，是指由公司董事会、管理层以及全体员工实 施的、旨在实现控制目标的过程。 第三条 内部控制的目标是： （一）确保国家有关法律、法规和公司内部规章制度的贯彻执行。 第四条 公司建立与实施内部控制制度，应遵循下列原则： （一）全面性原则。内部控制贯穿决策、执行、监督、反馈全过程，覆盖公 司及其所属企业的各种业务和事项。 （二）重要性原则。内部控制应当在全面控制的基础上，关注重要业务事项 和高风险领域； （三）有效性原则。公司任何人员不得拥有不受内部控制约束的权力，公司 全体人员应当维护内部控制制度的有效执行。 （四）独立性原则。内部控制的监督检查部门独 ...